Evaluation of Safety, Drug-Drug Interactions and Pharmacokinetic Profiles of Co-Administration of Betahistine With Olanzapine in Healthy Female Subjects

This study has been completed.
Sponsor:
Information provided by:
OBEcure Ltd.
ClinicalTrials.gov Identifier:
NCT00852956
First received: February 23, 2009
Last updated: May 3, 2009
Last verified: May 2009
  Purpose

This will be a phase I, randomized, two-arm, double-blind, placebo-controlled, sequential study in up to 50 healthy female subjects. The study will be comprised of three treatment periods for a total of 4 weeks treatment duration:

Period I 1 week (Days 1-7) administration of betahistine daily (three times per day; 144 mg/day total) or matching placebo.

Period II 1 week (Days 8-14) titration of olanzapine once daily (2.5 to 10 mg) and continuation of betahistine or matching placebo administration (daily; three times per day) Period III 2 weeks (Days 15-28) of continued co-administration of betahistine/matching placebo, three times per day, and olanzapine once daily (7.5 to 10 mg/day)


Condition Intervention Phase
Healthy
Drug: Betahistine
Phase 1

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Official Title: Evaluation of Safety, Drug-Drug Interactions and Pharmacokinetic Profiles of Co-Administration of Betahistine With Olanzapine in Healthy Female Subjects

Resource links provided by NLM:


Further study details as provided by OBEcure Ltd.:

Primary Outcome Measures:
  • The primary objectives are to evaluate the safety, tolerability, pharmacokinetic profiles and drug-drug interactions of betahistine and olanzapine at steady-state in healthy female subjects. [ Time Frame: 3 weeks ] [ Designated as safety issue: Yes ]

Estimated Enrollment: 50
Study Start Date: February 2009
Study Completion Date: April 2009
Primary Completion Date: April 2009 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Treatment
Betahistine 48 mg TID; 08:00, 13:00 and 18:00 (144 mg/day total)and Olanzapine (10 mg/day)
Drug: Betahistine

The study will be comprised of three treatment periods for a total of 4 weeks treatment duration:

Period I 1 week (Days 1-7) administration of betahistine 48 mg three times daily (144 mg/day total) or matching placebo Period II 1 week (Days 8-14) titration of olanzapine once daily (from 2.5 mg up to 10 mg) and continuation of betahistine or matching placebo administration (three times daily as in Period I) Period III 2 weeks (Days 15-28) of co-administration of betahistine or matching placebo (three times daily; as in Periods II and III) and olanzapine once daily (7.5 or 10 mg, as tolerated)

On Day 1, after a 7-day screening period, eligible subjects will be randomized to one of the two treatment groups in a 1:1 ratio:

Betahistine 48 mg TID; 08:00, 13:00 and 18:00 (144 mg/day total) Matching placebo TID; 08:00, 13:00 and 18:00

Active Comparator: Control
Matching placebo TID; 08:00, 13:00 and 18:00 and Olanzapine (10 mg/day).
Drug: Betahistine

The study will be comprised of three treatment periods for a total of 4 weeks treatment duration:

Period I 1 week (Days 1-7) administration of betahistine 48 mg three times daily (144 mg/day total) or matching placebo Period II 1 week (Days 8-14) titration of olanzapine once daily (from 2.5 mg up to 10 mg) and continuation of betahistine or matching placebo administration (three times daily as in Period I) Period III 2 weeks (Days 15-28) of co-administration of betahistine or matching placebo (three times daily; as in Periods II and III) and olanzapine once daily (7.5 or 10 mg, as tolerated)

On Day 1, after a 7-day screening period, eligible subjects will be randomized to one of the two treatment groups in a 1:1 ratio:

Betahistine 48 mg TID; 08:00, 13:00 and 18:00 (144 mg/day total) Matching placebo TID; 08:00, 13:00 and 18:00


  Eligibility

Ages Eligible for Study:   18 Years to 45 Years
Genders Eligible for Study:   Female
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  1. Healthy female subjects 18 to 45 years of age.
  2. Signed written informed consent.
  3. Willing and able to comply with study procedures (including staying overnight in the research facility for required period for PK sampling).
  4. Regular menstrual period.
  5. All subjects should be non-lactating, have a negative urine pregnancy test result, and do not plan on become pregnant during the study, must practice or be willing to continue to practice appropriate birth control (such as implants, injectables, oral contraceptives, some intrauterine contraceptive devices, sexual abstinence, tubal ligation, or a vasectomized partner) during the entire study duration.
  6. Has been on a stable treatment regimen with any of the following medications for a minimum of 90 days prior to screening:

    • Hormone replacement therapy;
    • Oral contraceptives.

Exclusion Criteria:

  1. Has abnormal body composition, either overweight or obesity (BMI > 27 Kg/m2) or undernourishment (BMI < 18.5 Kg/m2).
  2. Has had a significant body weight loss of >4 kg in the 90 days prior to screening.
  3. Pregnancy or lactation.
  4. Has recently started a smoking cessation program.
  5. Has known sensitivity to betahistine or olanzapine.
  6. Having first degree relatives with diabetes.
  7. Personal history of gestational diabetes.
  8. Subjects diagnosed with polycystic ovary disease.
  9. Has a clinically significant history or presence of any of the following conditions:

    • Active or past history of cardiovascular or cerebrovascular disease including unstable angina, myocardial infarction, transient ischemic attacks/stroke, clinically significant arrhythmia, congestive heart failure, or cardiac valve abnormalities
    • Diabetes mellitus (type 1 or 2)
    • Fasting blood glucose level > 100 mg/dL or HBA1c > 6.0% at screening.
    • Renal insufficiency defined as a serum creatinine >1.5 mg/dL (133 µmol/L) at screening
    • Malignant disease within 5 years of screening
    • Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) >2 ULN
    • Thyroid-stimulating hormone (TSH) outside of the normal range
    • Plans on having any surgery (elective or otherwise) during the course of the study
    • Has hypertension (sitting blood pressure >140/90 mmHg at screening or randomization),
    • Has hyperlipidemia (triglycerides [TG] >200 mg/dL or low-density lipoprotein cholesterol [LDL-C] >190 mg/dL),
    • History of asthma
    • History of peptic ulcers
    • History of HIV, Hepatitis B, Hepatitis C
    • Has clinical laboratory test values (chemistry, hematology, metabolic or urinalysis) judged to be clinically significant by the investigator
    • Has a physical examination or electrocardiogram (ECG) with significant abnormalities, as judged by the investigator
    • Currently abuses drugs or alcohol or has a history of abuse that in the investigator's opinion could cause the subject to be noncompliant with study procedures
    • Has psychiatric or neurological disorders requiring chronic medications (e.g., antidepressants, anti-psychotic or anti anxiety agents).
    • Chronic or as needed use of antihistamines
  10. Has been treated over the past 60 days, is currently treated, or is expected to require or undergo treatment with any medications for a period of more than 3 days (with the exception of antibiotic treatment for a period of less than 7 days).
  11. Has received any investigational drug within 90 days prior to screening.
  12. Is an immediate family member of personnel directly affiliated with the study at the investigative site, or is personally directly affiliated with the study at the investigative site; or is employed by OBEcure Ltd.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00852956

Locations
Romania
IFE Human Pharmacology
Arad, Romania
IFE Human Pharmacology
Timisoara, Romania
Sponsors and Collaborators
OBEcure Ltd.
  More Information

No publications provided

Responsible Party: Nir Barak, OBEcure Ltd
ClinicalTrials.gov Identifier: NCT00852956     History of Changes
Other Study ID Numbers: OBE 209
Study First Received: February 23, 2009
Last Updated: May 3, 2009
Health Authority: Romania: Ministry of Public Health

Keywords provided by OBEcure Ltd.:
Betahistine
Olanzapine
Safety of co-administration of Betahistien and Olanzapine

Additional relevant MeSH terms:
Betahistine
Olanzapine
Histamine Agonists
Histamine Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Physiological Effects of Drugs
Vasodilator Agents
Cardiovascular Agents
Therapeutic Uses
Antipsychotic Agents
Tranquilizing Agents
Central Nervous System Depressants
Central Nervous System Agents
Psychotropic Drugs
Serotonin Uptake Inhibitors
Neurotransmitter Uptake Inhibitors
Serotonin Agents
Antiemetics
Autonomic Agents
Peripheral Nervous System Agents
Gastrointestinal Agents

ClinicalTrials.gov processed this record on July 22, 2014